BMS-181885, a 5-HT(1B/1D) receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential

European Journal of Pharmacology

Volumn 351, Issue 3, 1998, Pages 329-339

  Saxena, Pramod R ^a   De Vries, Peter ^a   Heiligers, Jan P C ^a   Bax, Willem A ^a   MaassenVanDenBrink, Antoinette ^a   Yocca, Frank D ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antimigraine drug; Arteriovenous anastomosis; BMS 181885; Carotid artery; Coronary artery, human; Human; Migraine; Pig; Sumatriptan

Indexed keywords

BMS 181885; SEROTONIN 1 AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOVENOUS FISTULA; ARTICLE; CAROTID ARTERY FLOW; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; HEADACHE; HEMODYNAMICS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; ARTERIOVENOUS ANASTOMOSIS; CAROTID ARTERIES; CORONARY VESSELS; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; JUGULAR VEINS; MIGRAINE DISORDERS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; OXYGEN; PIPERAZINES; POTASSIUM; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUBSTANCE P; SUMATRIPTAN; SWINE; VASOCONSTRICTOR AGENTS;

EID: 0031829085     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00325-2     Document Type: Article

References (62)

1. Bax, W.A., Saxena, P.R., 1993. Sumatriptan and ischaemic heart disease. Lancet 341, 1420.
2. 1D-like receptors, and a comparison with grafted veins. Naunyn-Schmiedeberg's Arch. Pharmacol. 345, 500-508.
3. Bax, W.A., Renzenbrink, G.J., van Heuven-Nolsen, D., Thijssen, H.J.M., Bos, E., Saxena, P.R., 1993. 5-HT receptors mediating contractions of the isolated human coronary artery. Eur. J. Pharmacol. 239, 203-210.
4. Beattie, D.T., Connor, H.E., Feniuk, W., Humphrey, P.P.A., 1994. The pharmacology of sumatriptan. Rev. Contemp. Pharmacother. 5, 285-294.
5. Bossaller, C., Habib, G.B., Yamamoto, H., Williams, C., Wells, S., Henry, P.D., 1987. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J. Clin. Invest. 79, 170-174.
6. Bouchelet, I., Cohen, Z., Case, B., Seguela, P., Hamel, E., 1996. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50, 219-223.
7. Brändli, P., Loffler, B.M., Breu, V., Osterwalder, R., Maire, J.P., Clozel, M., 1996. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64, 315-322.
8. Chester, A.M., Martin, G.R., Bodelsson, M., Arneklo-Nobin, B., Tadjkarimi, S., Tornebrandt, K., Yacoub, M.H., 1990. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc. Res. 24, 932-937.
9. Chester, A.M., O'Neil, G.S., Yacoub, M.H., 1993. Sumatriptan and ischaemic heart disease. Lancet 341, 1419-1420.
10. 1D antagonists. J. Med. Chem. 37, 2253-2257.
11. 2 receptor activation. Eur. J. Pharmacol. 161, 91-94.
12. De Lean, A., Munson, P.J., Rodbard, D., 1978. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235, E97-E102.
13. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br. J. Pharmacol. 102, 323-330.
14. 1-like receptors. Br. J. Pharmacol. 104, 183-189.
15. 1D receptors involved?. Naunyn-Schmiedeberg's Arch. Pharmacol. 345, 509-515.
16. Den Boer, M.O., Van Woerkens, L.J., Somers, J.A., Duncker, D.J., Lachmann, B., Saxena, P.R., Verdouw, P.D., 1993. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J. Appl. Physiol. 75, 782-789.
17. 1D receptor antagonist. Br. J. Pharmacol. 118, 85-92.
18. 1B/D receptor ligand, with functional 5-HT receptors. Naunyn-Schmiedeberg' s Arch. Pharmacol. 355, 423-430.
19. 1B/1D and novel receptors. Br. J. Pharmacol. 123, 1561-1570.
20. Diener, H.C., 1995. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. 6th International Headache Research Seminar, Copenhagen, Denmark.
21. 1A receptor agonist flesinoxan in the cat. J. Cardiovasc. Pharmacol. 14, 770-776.
22. Feniuk, W., Humphrey, P.P.A., Perren, M.J., 1989. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br. J. Pharmacol. 96, 83-90.
23. Ferrari, M.D., 1991. Treatment of migraine attacks with sumatriptan. New Engl. J. Med. 325, 316-321.
24. Ferrari, M.D., Saxena, P.R., 1993. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. 14, 129-133.
25. Goldstein, D., 1996. Clinical trials of tachykinin antagonists. Conference on Tachykinins and their antagonists, London, UK.
26. 1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation. Br. J. Pharmacol. 116, 2385-2390.
27. 1D binding sites. Br. J. Pharmacol. 102, 227-233.
28. 1Dβ receptors. Eur. J. Pharmacol. 242, 75-82.
29. Heyck, H., 1969. Pathogenesis of migraine. Res. Clin. Stud. Headache 2, 1-28.
30. 1-like receptor in dog isolated saphenous vein. Br. J. Pharmacol. 94, 1123-1132.
31. Humphrey, P.P.A., Apperly, E., Feniuk, W., Perren, M.J., 1990. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (Eds.), Cardiovascular Pharmacology of 5-Hydroxytryptamine, Prospective Therapeutic Applications. Kluwer Academic Publishers, Dordrecht, pp. 417-428.
32. Johnston, B.M., Saxena, P.R., 1978. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br. J. Pharmacol. 63, 541-549.
33. 1DB receptors. Circulation 90, 1141-1153.
34. Lee, W.S., Moskowitz, M.A., 1993. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res. 626, 303-305.
35. Maassen VanDenBrink, A., Bax, W.A., Ferrari, M.D., Zijlstra, F.J., Bos, E., Saxena, P.R., 1996. Augmented contraction of the human isolated coronary artery by sumatriptan; a possible role for endogenous thromboxane. Br. J. Pharmacol. 119, 855-862.
36. Maassen VanDenBrink, A.M., Reekers, A., Bax, W.A., Ferrari, M.D., Saxena, P.R., 1998. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation, in press.
37. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87, 401-405.
38. May, A., Gijsman, H.J., Wallnöfer, A., Jones, R., Diener, H.C., Ferrari, M.D., 1996. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67, 375-378.
39. 1B/D receptor antagonist GR127935. CNS Drug Rev. 2, 415-428.
40. 1D binding sites. Eur. J. Pharmacol. 163, 133-136.
41. Perren, M.J., Feniuk, W., Humphrey, P.P.A., 1989. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 (Suppl. 9), 41-46.
42. Phebus, L.A., Johnson, K.W., Stengel, P.W., Lobb, K.L., Nixon, J.A., Hipskind, P.A., 1997. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci. 60, 1553-1561.
43. Ploeg, R.J., Van Bockel, J.H., Langendijk, P.T.J., Groenewegen, M., Van der Woude, F.J., Persijn, G.G., Thorogood, J., Hermans, J., 1992. Effect of preservation solution on results of cadaveric kidney transplantation. Lancet 340, 129.
44. Roon, K., Diener, H.C., Ellis, P., Hettiarachchi, J., Poole, P., Christiansen, L., Ferrari, M.D., Olesen, J., 1997. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials. Cephalalgia 17, 245.
45. Saxena, P.R., 1985. An interactive computer programme for data management and parametric and non-parametric statistical analysis. Br. J. Pharmacol. 86, 818P.
46. Saxena, P.R., 1990. Is there still a case for the shunt hypothesis in migraine? In: Sandier, M., Collins, G.M. (Eds.), Migraine: A Spectrum of Ideas. Oxford Univ. Press, Oxford, pp. 191-199.
47. Saxena, P.R., 1995. Cranial arteriovenous shunting: an in vivo animal model for migraine. In: Olesen, J., Moskowitz, M.A. (Eds.), Experimental Headache Models in Animal and Man. Lippincott-Raven Publishers, Philadelphia, pp. 189-198.
48. Saxena, P.R., De Vlaam-Schluter, G.M., 1974. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine. Studies in an animal experimental model for migraine. Headache 13, 142-163.
49. 1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol. Sci. 10, 200-204.
50. 1D receptor agonists. Exp. Opin. Invest. Drugs 5, 581-593.
51. Saxena, P.R., Tfelt-Hansen, P., 1993. Sumatriptan. In: Olesen, J., Tfelt-Hansen, P., Welch, K.M.A. (Eds.), The Headaches. Raven Press, New York, pp. 329-341.
52. Saxena, P.R., Verdouw, P.D., 1982. Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J. Physiol. (London) 332, 501-520.
53. Saxena, P.R., Villalón, C.M., 1990. Cardiovascular effects of serotonin agonists and antagonists. J. Cardiovasc. Pharmacol. 15, S17-34.
54. Saxena, P.R., Schamhardt, H.C., Forsyth, R.P., Hoeve, J., 1980. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput. Progr. Biomed. 12, 63-84.
55. 1-like' receptors. Naunyn-Schmiede3 berg's Arch. Pharmacol. 333, 198-204.
56. 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn-Schmiedeberg's Arch. Pharmacol. 355, 295-302.
57. Schamhardt, H.C., Verdouw, P.D., Van Der Hoek, T.M., Saxena, P.R., 1979. Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis. J. Cardiovasc. Pharmacol. 1, 673-686.
58. 1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34, 255-261.
59. 1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36, 525-533.
60. 1D receptor antagonist. Behav. Brain Res. 73, 157-161.
61. 1D agonist properties. Cephalalgia 17, 404.
62. 1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea-pig dura mater. Neuropharmacology 36, 83-91.